Please use this identifier to cite or link to this item: https://hdl.handle.net/10137/11649
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcGuinness, Sarah L-
dc.contributor.authorHolt, Deborah C-
dc.contributor.authorHarris, Tegan M-
dc.contributor.authorWright, Connor-
dc.contributor.authorBaird, Rob-
dc.contributor.authorGiffard, Phillip M-
dc.contributor.authorBowen, Asha C-
dc.contributor.authorTong, Steven Y C-
dc.date.accessioned2021-02-12T03:17:04Z-
dc.date.available2021-02-12T03:17:04Z-
dc.date.issued2021-02-10-
dc.identifier.citationCopyright © 2021 McGuinness et al.-
dc.identifier.citationmSphere. 2021 Feb 10;6(1):e00651-20. doi: 10.1128/mSphere.00651-20.-
dc.identifier.other101674533-
dc.identifier.urihttps://hdl.handle.net/10137/11649-
dc.description.abstractRecently, we identified a Staphylococcus aureus sequence type 5 (ST5) clone in northern Australia with discrepant trimethoprim-sulfamethoxazole (SXT) susceptibility results. We aimed to identify isolates of this clone using Vitek 2 SXT resistance as a proxy and to compare its epidemiology with those of other circulating S. aureus strains. We collated Vitek 2 susceptibility data for S. aureus isolates collected through our laboratory and conducted a prospective, case-control study comparing clinical, microbiological, epidemiological, and genomic data for subsets of isolates reported as SXT resistant (cases) and SXT susceptible (controls) by Vitek 2. While overall SXT resistance rates remained relatively stable from 2011 to 2018 among 27,721 S. aureus isolates, non-multidrug-resistant methicillin-resistant S. aureus (MRSA) strains almost completely replaced multidrug-resistant MRSA strains as the predominant SXT-resistant MRSA phenotype. Demographic and clinical features of 51 case-control pairs were similar, but genotyping revealed stark differences: clonal complex 5 (CC5) MRSA predominated among SXT-resistant cases (34/51 [67%]), while CC93 MRSA predominated among susceptible controls (26/51 [51%]). All CC5 isolates were an ST5 clonal lineage that possessed the trimethoprim resistance gene dfrG within SCCmec IVo; all were SXT susceptible by Etest. The replacement of Vitek 2 reported SXT-resistant multidrug-resistant MRSA by non-multidrug-resistant MRSA appears related to the emergence of an ST5-MRSA-SCCmec IVo clone that is SXT susceptible by Etest and causes clinical disease similar to that caused by ST93-MRSA-SCCmec IVa. Reliance on Vitek 2 SXT reporting may lead to unnecessary restriction of effective oral treatment options for S. aureus infections. Whether the presence of dfrG within SCCmec IVo provides a selective advantage at the population level is currently unclear.IMPORTANCE Staphylococcus aureus is an important human pathogen that causes a wide range of clinical infections. In the past 2 decades, an epidemic of community-associated skin and soft tissue infections has been driven by S. aureus strains with specific virulence factors and resistance to beta-lactam antibiotics. Recently, an S. aureus strain with discrepant antimicrobial susceptibility testing results has emerged in northern Australia. This ST5-MRSA-SCCmec IVo clone is reported as resistant to trimethoprim-sulfamethoxazole by Vitek 2 but susceptible by phenotypic methods. ST5-MRSA-SCCmec IVo is now the second most common community-associated MRSA clone in parts of Australia and causes a spectrum of clinical disease similar to that caused by the virulent ST93-MRSA lineage. Whole-genome sequence analysis demonstrates that ST5-MRSA-SCCmecIVo is causing a clonal outbreak across a large geographical region. Although phenotypic testing suggests in vitro susceptibility to trimethoprim-sulfamethoxazole, it is unclear at this stage whether the presence of dfrG within SCCmec IVo provides a selective advantage at the population level.-
dc.language.isoeng-
dc.titleClinical and Molecular Epidemiology of an Emerging Panton-Valentine Leukocidin-Positive ST5 Methicillin-Resistant Staphylococcus aureus Clone in Northern Australia.-
dc.typeJournal Article-
dc.publisher.placeUnited States-
dc.identifier.journaltitlemSphere-
dc.identifier.doi10.1128/mSphere.00651-20-
dc.identifier.orcid0000-0002-5725-0102-
dc.identifier.orcid0000-0002-9312-7451-
dc.identifier.orcid0000-0002-1368-8356-
dc.identifier.pubmedurihttps://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/33568451-
dc.description.affiliationDepartment of Infectious Diseases, Royal Darwin Hospital, Darwin, Northern Territory, Australia sarah.mcguinness@monash.edu steven.tong@mh.org.au.-
dc.description.affiliationDepartment of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.-
dc.description.affiliationDepartment of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, Victoria, Australia.-
dc.description.affiliationGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.-
dc.description.affiliationCollege of Health and Human Sciences, Charles Darwin University, Darwin, Northern Territory, Australia.-
dc.description.affiliationDepartment of Infectious Diseases, Royal Darwin Hospital, Darwin, Northern Territory, Australia.-
dc.description.affiliationMicrobiology, Territory Pathology, Royal Darwin Hospital, Darwin, Northern Territory, Australia.-
dc.description.affiliationPerth Children's Hospital, Perth, Western Australia, Australia.-
dc.description.affiliationWesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.-
dc.description.affiliationSchool of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia.-
dc.description.affiliationGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia sarah.mcguinness@monash.edu steven.tong@mh.org.au.-
dc.description.affiliationVictorian Infectious Disease Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia.-
dc.description.affiliationDoherty Department, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.-
dc.source.volume6-
local.issue.number2379-5042 (Electronic)-
local.issue.number2379-5042 (Linking)-
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.


Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing

Pubmed

PubMed References

Who's citing